Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector.
Podsakoff
G M
GM
Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, MS #62, Los Angeles, California 90027, USA. gpodsakoff@chla.usc.edu
D000163:Acquired Immunodeficiency Syndrome / Q000235:genetics / Q000628:therapy*; D026683:Advisory Committees; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D004274:DNA, Recombinant / Q000009:adverse effects / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods* / Q000592:standards*; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D009316:National Institutes of Health (U.S.); D014481:United States
D019380:Anti-HIV Agents; D004274:DNA, Recombinant